Anti-BCMA Chimeric Antigen Receptor T Cells for Relapsed or Refractory Multiple Myeloma
Summary
Third Opinion Trial Synopsis:
This study is to see if a new treatment called anti-BCMA CAR T therapy is safe for people with RRMM. It is an open study, which means the participants and doctors both know what treatment is being given.
This study is to see if a new treatment called anti-BCMA CAR T therapy is safe for people with RRMM. It is an open study, which means the participants and doctors both know what treatment is being given.
*Third Opinion AI Generated Synopsis
Trial Summary
This is an open-label study to determine the safety of anti-B-cell maturation antigen (BCMA) Chimeric antigen receptor T-cell (CAR T) therapy in participants with Relapsed or Refractory Multiple Myeloma (RRMM).
This is an open-label study to determine the safety of anti-B-cell maturation antigen (BCMA) Chimeric antigen receptor T-cell (CAR T) therapy in participants with Relapsed or Refractory Multiple Myeloma (RRMM).
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts:
